Cerenion awarded a key patent on its C-Trend® technology in Japan
A few weeks after obtaining patents in Europe and the USA, Cerenion has been granted a key patent on its technology in Japan. The company has developed the world’s first practical method for measuring the brain function of intensive care patients.
“This latest patent represents a significant expansion of the protection for our IPR on a major future market”, remarks Dr. Jukka Kortelainen, Chief Medical Officer and head of IPR management at Cerenion.
Cerenion has filed multiple intellectual property applications on its technology worldwide.